In lat­est can­cer deal, Bris­tol My­ers Squib­b's new BD chief bets $65M in search for more tar­gets like PARP

Eliz­a­beth Mi­ly, the new chief of the strat­e­gy and busi­ness de­vel­op­ment group at Bris­tol My­ers Squibb, has struck her first high-pro­file col­lab­o­ra­tion since suc­ceed­ing Paul Bion­di. In putting down $65 mil­lion up­front, she’s al­so sig­nal­ing where the phar­ma gi­ant — with a new­ly-con­sol­i­dat­ed pipeline fea­tur­ing a slate of on­col­o­gy and hema­tol­ogy drugs from Cel­gene — is head­ed for the next wave of can­cer ther­a­pies.

Lloyd Se­gal

Syn­thet­ic lethal­i­ty is the theme at Ver­sant-backed Re­pare Ther­a­peu­tics, which is get­ting $50 mil­lion in cash and $15 mil­lion in eq­ui­ty in­vest­ment to dis­cov­er new tar­gets for Bris­tol. Its own clin­i­cal and near-clin­i­cal pro­grams will re­main in­de­pen­dent, CEO Lloyd Se­gal said.

“This col­lab­o­ra­tion will help to en­sure that our nov­el dis­cov­er­ies are be­ing broad­ly pros­e­cut­ed in the search for the next gen­er­a­tion of pre­ci­sion on­col­o­gy med­i­cines,” he added.

The cen­tral idea is that while tu­mors can tol­er­ate in­di­vid­ual de­fects in DNA, si­mul­ta­ne­ous per­tur­ba­tion of more than one gene can lead to can­cer cell death. PARP in­hibitors are the most of­ten cit­ed ex­am­ple, as these drugs — like As­traZeneca’s Lyn­parza and GSK’s Ze­ju­la — work by hit­ting the en­zyme that tu­mors with BR­CA mu­ta­tions re­ly on heav­i­ly to re­pair their DNA.

But that tar­get is on­ly “the tip of the ice­berg,” Ver­sant man­ag­ing di­rec­tor Jer­el Davis told End­points News in 2017.

Eliz­a­beth Mi­ly

Re­pare brings to the ta­ble a CRISPR-based plat­form that scours the genome for mu­ta­tions that be­come lethal to can­cer cells when they hap­pen to­geth­er. Re­searchers start with an iden­ti­fied “le­sion,” or im­por­tant mu­ta­tions, such as BR­CA. Then they screen for po­ten­tial new tar­gets by lever­ag­ing the DNA cut­ting pow­ers of CRISPR.

The ap­proach promis­es to be tu­mor-ag­nos­tic, find­ing tar­gets that are present in a range of tu­mors — some­thing the PARP pi­o­neers have demon­strat­ed with their for­ay in­to prostate can­cer af­ter an ini­tial fo­cus on breast and ovar­i­an tu­mors.

Ru­pert Vessey, the ex-Cel­gene ex­ec who’s now EVP of re­search and ear­ly de­vel­op­ment at Bris­tol, of­fered his thumbs up to the “dis­tinc­tive” tech­nol­o­gy.

The phar­ma gi­ant has ex­clu­sive rights to de­vel­op and com­mer­cial­ize ther­a­pies — most like­ly small mol­e­cules — that hit the tar­gets found un­der the deal. Re­pare, which has of­fices in both Mon­tre­al and Boston, is el­i­gi­ble for up to $3 bil­lion in li­cense fees and oth­er mile­stones.

Trans­port Sim­u­la­tion Test­ing for Your Ther­a­py is the Best Way to As­sure FDA Ex­pe­dit­ed Pro­gram Ap­proval

Modality Solutions is an ISO:9001-registered biopharmaceutical cold chain engineering firm with unique transport simulation capabilities that support accelerated regulatory approval for biologics and advanced therapeutic medicinal products (ATMP). Our expertise combines traditional validation engineering approaches with regulatory knowledge into a methodology tailored for the life sciences industry. We provide insight and execution for the challenges faced in your cold chain logistics network.

Jeff Albers, Blueprint CEO

Di­ag­nos­tic champ Roche buys its way in­to the RET ti­tle fight with Eli Lil­ly, pay­ing $775M in cash to Blue­print

When Roche spelled out its original $1 billion deal — $45 million of that upfront — with Blueprint to discover targeted therapies against immunokinases, the biotech partner’s RET program was still preclinical. Four years later, pralsetinib is on the cusp of potential approval and the Swiss pharma giant is putting in much more to get in on the commercial game.

Roche gains rights to co-develop and co-commercialize the drug, with sole marketing responsibility for places outside the US and China (where CStone has staked its claim).

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 85,200+ biopharma pros reading Endpoints daily — and it's free.

Ludwig Hantson, Alexion CEO

Why pay $4B for a steady di­et of dis­ap­point­ment? Porges turns thumbs down on Alex­ion’s M&A strat­e­gy, of­fers some point­ers

When Alexion announced recently that it was paying $1.4 billion to bag Portola and its underperforming Factor Xa inhibitor reversal agent, you could hear the head-scratching going on around virtual Wall Street.

Why was Alexion going down the discount lane for new products? And why something like this? Analysts have been urging Alexion to get serious about M&A for years if it was serious about diversifying the company beyond Soliris and its successor drug. But this wasn’t the kind of heavy-impact deal they were looking for.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 85,200+ biopharma pros reading Endpoints daily — and it's free.

Sanofi keeps foot on the gas, agree­ing to five-year col­lab­o­ra­tion with MD An­der­son

Just four months after scoring its first cancer drug approval in a decade, Sanofi is staying on the oncology offensive.

The French pharma is planning to accelerate the development of potential treatments, partnering with the University of Texas MD Anderson Cancer Center in a five-year collaboration. By combining Sanofi’s pipeline with MD Anderson’s top-notch clinical trial program in oncology, the pair will launch biomarker-driven clinical studies to better understand which drug cocktails can effectively curb cancer progression.

President Trump (left) and NIAID chief Anthony Fauci in the White House press room, April 22, 2020 (Michael Reynolds/Sipa via AP Images)

White House tries to dis­cred­it An­tho­ny Fau­ci — could he be on his way out?

For two months in late winter and early spring, Anthony Fauci and President Trump stood in uneasy co-existence at White House briefings — an unlikely truce between an infectious disease official who had helped combat AIDS and Ebola and a president who repeatedly denied the danger of a virus that would go on to kill 100,000 Americans, repeatedly rejected masks and certain social distancing efforts, and promoted a drug with little scientific basis.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 85,200+ biopharma pros reading Endpoints daily — and it's free.

Stéphane Bancel, Moderna CEO (Andrew Harnik/AP Images)

A top an­a­lyst turns the spot­light on Mod­er­na, fu­el­ing a fast-and-fu­ri­ous Street race over the fu­ture of mR­NA

Bioregnum Opinion Column by John Carroll

Four months ago, one of the favorite talking points on the biopharma social media wave length was whether Moderna shares $MRNA were priced right or were wildly inflated.

After all, said the naysayers, the company had never actually pushed a treatment to an approval. Did messenger RNA really work, coding cells to make a drug or a vaccine? And how about all that chatter about how ‘secretive’ they are, or were?

Now, as CEO Stéphane Bancel and the top execs push the company to the forefront of a frantic race to develop the first vaccine to fight against the reignited wildfire spread of Covid-19, all those questions have been magnified — along with the stock price.

Endpoints Premium

Premium subscription required

Unlock this article along with other benefits by subscribing to one of our paid plans.

Cy­to­ki­net­ics nabs Chi­nese part­ner, up to $450M as CV be­comes com­pa­ny fo­cus

Cytokinetics’ ALS programs may have seen better days, but its cardiovascular division has attracted well-backed partners, including Amgen and Royalty Pharma, who, in 2017 paid $90 million in exchange for a 4.5% royalty on their lead heart drug.

Now a Chinese drugmaker and a major investor are signing onto their second cardiovascular candidate, an experimental drug known as CK-274 and designed to treat hypertrophic cardiomyopathies — genetic conditions that cause heart muscles to become abnormally and potentially dangerously thick. Ji Xing Pharmaceuticals will pay Cytokinetics $25 million upfront for the rights to commercialize the drug in China and certain neighboring regions, along with $200 million in potential milestones.

Bil­lions of dol­lars worth of SPACs are rid­ing on the biotech IPO boom

Billionaire hedge fund manager Bill Ackman’s push to raise $4 billion for his blank check company, Pershing Square Tontine Holdings, is casting a spotlight on the SPACs. And amid a historic SPAC boom, biotechs are setting several records on what some observers say is shaping up to be a third major track — besides IPO and M&A — to go public.

“SPACs were approximately 3% of the IPO market back in 2014, now they are almost 35% of all new listings,” Jay Heller, the Nasdaq’s head of capital markets, told Endpoints News.

Andrew Allen, Gritstone Oncology CEO

A neoanti­gen pi­o­neer says its tech is work­ing great. So what wrecked the share price?

Gritstone Oncology was one of the original neoantigen upstarts, raising cash and planning to disrupt the immuno-oncology field with a bold new approach to fighting cancer with a new brand of vaccines.

On Monday, the crew in charge ran out a full display of what they’ve been seeing in a Phase I study. And everything seems to be working perfectly with one big exception: It didn’t significantly shrink tumors, let alone eradicate them.

Endpoints Premium

Premium subscription required

Unlock this article along with other benefits by subscribing to one of our paid plans.